ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 31.19 Billion KRW | 773.79% |
| 2022 | 9.41 Billion KRW | -35.59% |
| 2021 | 14.61 Billion KRW | -45.98% |
| 2020 | 27.04 Billion KRW | 149.7% |
| 2019 | 10.83 Billion KRW | 488.05% |
| 2018 | 1.84 Billion KRW | 94.9% |
| 2017 | 945.04 Million KRW | 66.68% |
| 2016 | 566.99 Million KRW | -87.44% |
| 2015 | 4.51 Billion KRW | 16.44% |
| 2014 | 3.87 Billion KRW | 2.65% |
| 2013 | 3.77 Billion KRW | 10.46% |
| 2012 | 3.41 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 9.71 Billion KRW | -95.2% |
| 2024 Q1 | 31.93 Billion KRW | 2728.92% |
| 2023 FY | 82.22 Billion KRW | 773.79% |
| 2023 Q3 | 4.04 Billion KRW | -82.92% |
| 2023 Q4 | 1.12 Billion KRW | -72.12% |
| 2023 Q2 | 23.7 Billion KRW | 1432.7% |
| 2023 Q1 | 1.54 Billion KRW | -77.11% |
| 2022 FY | 9.41 Billion KRW | -35.59% |
| 2022 Q4 | 6.75 Billion KRW | 554.79% |
| 2022 Q3 | 1.03 Billion KRW | 429.98% |
| 2022 Q2 | -312.76 Million KRW | -138.7% |
| 2022 Q1 | 808.27 Million KRW | -90.64% |
| 2021 Q3 | -5.67 Billion KRW | -318.61% |
| 2021 Q4 | 8.63 Billion KRW | 252.22% |
| 2021 Q1 | 7.01 Billion KRW | 375.17% |
| 2021 FY | 14.61 Billion KRW | -45.98% |
| 2021 Q2 | 2.59 Billion KRW | -63.03% |
| 2020 Q2 | 7.53 Billion KRW | 52.93% |
| 2020 Q4 | -2.55 Billion KRW | -129.1% |
| 2020 Q3 | 8.76 Billion KRW | 16.31% |
| 2020 FY | 27.04 Billion KRW | 149.7% |
| 2020 Q1 | 4.92 Billion KRW | -49.62% |
| 2019 Q3 | -189.71 Million KRW | -117.4% |
| 2019 Q1 | 332.61 Million KRW | 64.11% |
| 2019 FY | 10.83 Billion KRW | 488.05% |
| 2019 Q4 | 9.78 Billion KRW | 5255.77% |
| 2019 Q2 | 1.09 Billion KRW | 227.86% |
| 2018 FY | 1.84 Billion KRW | 94.9% |
| 2018 Q4 | 202.68 Million KRW | -3.7% |
| 2018 Q3 | 210.47 Million KRW | -4.16% |
| 2018 Q2 | 219.62 Million KRW | -81.71% |
| 2018 Q1 | 1.2 Billion KRW | 285.05% |
| 2017 Q2 | -482.58 Million KRW | -122.03% |
| 2017 FY | 945.04 Million KRW | 66.68% |
| 2017 Q4 | -648.85 Million KRW | -1011.1% |
| 2017 Q1 | 2.19 Billion KRW | 1375.76% |
| 2017 Q3 | -58.39 Million KRW | 87.9% |
| 2016 Q2 | 265.09 Million KRW | 498.22% |
| 2016 Q4 | 148.46 Million KRW | -2.79% |
| 2016 FY | 566.99 Million KRW | -87.44% |
| 2016 Q1 | 44.31 Million KRW | -96.82% |
| 2016 Q3 | 152.72 Million KRW | -42.39% |
| 2015 Q2 | 94.15 Million KRW | -93.54% |
| 2015 Q1 | 1.45 Billion KRW | 149.79% |
| 2015 FY | 4.51 Billion KRW | 16.44% |
| 2015 Q4 | 1.39 Billion KRW | 173.81% |
| 2015 Q3 | 508.7 Million KRW | 440.27% |
| 2014 Q4 | 583.78 Million KRW | -26.06% |
| 2014 FY | 3.87 Billion KRW | 2.65% |
| 2014 Q1 | 1.11 Billion KRW | 42.58% |
| 2014 Q2 | 1.38 Billion KRW | 24.39% |
| 2014 Q3 | 789.58 Million KRW | -43.08% |
| 2013 FY | 3.77 Billion KRW | 10.46% |
| 2013 Q1 | 1.1 Billion KRW | 0.0% |
| 2013 Q2 | 1.1 Billion KRW | 0.0% |
| 2013 Q4 | 782.1 Million KRW | 0.0% |
| 2013 Q3 | 782.1 Million KRW | -29.27% |
| 2012 FY | 3.41 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 618.896% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | -584.048% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 44.933% |
| Bioneer Corporation | 199.25 Billion KRW | 84.342% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | -1309.505% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 22.361% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -2041.278% |
| Helixmith Co., Ltd | 2.12 Billion KRW | -1370.345% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 87.774% |
| Medy-Tox Inc. | 128.16 Billion KRW | 75.657% |
| Peptron, Inc. | 1.14 Billion KRW | -2635.325% |
| Amicogen, Inc. | 51.51 Billion KRW | 39.435% |
| Genexine, Inc. | 387.48 Million KRW | -7951.552% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | -366.049% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | -75.299% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 82.882% |
| SillaJen, Inc. | 1.45 Billion KRW | -2041.664% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | -17.367% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | -116.321% |
| Genomictree Inc. | -1.03 Billion KRW | 3103.922% |
| MedPacto, Inc. | -1.83 Billion KRW | 1802.359% |
| D&D Pharmatech | 18.67 Billion KRW | -67.042% |
| EASY BIO,Inc. | 50.88 Billion KRW | 38.689% |
| GI Innovation, Inc. | 1.98 Billion KRW | -1468.22% |